CAMBRIDGE, Mass.–(BUSINESS WIRE) December 29, 2021 — Amylyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate (PB) and…Original Article
Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS
